MedTrace Logo

Abiraterone-Rechallenge Study for CRPC Patients

NCT02656615 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2017-03-24

No results posted yet for this study

Summary

To assess activity of abiraterone-re-challenge in patients with advanced prostate cancer and prior response to abiraterone.

Conditions

Interventions

DRUG

abiraterone acetate

Abiraterone acetate 1000 mg once daily and Prednisone 2x5 mg daily (continuously as per prescription label).

Sponsors & Collaborators

  • Cantonal Hospital of St. Gallen

    collaborator OTHER

  • University Hospital, Basel, Switzerland

    collaborator OTHER

  • Aurelius Omlin

    lead OTHER

Principal Investigators

  • Aurelius G Omlin, MD · Cantonal Hospital St. Gallen

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2017-02-28
Completion
2017-02-28

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02656615 on ClinicalTrials.gov